Acquisition / mergerFiled on BSE ·
Bajaj Healthcare reports Q2 & H1 FY27 results with revenue and profit growth
Bajaj Healthcare · Pharmaceuticals & Biotechnology
What the filing says
- Q2 FY27 revenue at ₹175.9 crore, up 18.9% YoY; EBITDA ₹32.1 crore, up 12.2% YoY; PAT ₹14.1 crore, up 26.9% YoY
- API exports grew 28.5% YoY to ₹62.6 crore; formulations revenue up 82% YoY to ₹41.7 crore with launch of Cenobamate tablets
- India Ratings upgraded long-term credit rating to IND A/Stable; earnings call scheduled for October 19, 2026, at 5 PM IST
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Bajaj Healthcare
- Acquisition / mergerBajaj Healthcare Limited announces unaudited Q2 and H1 FY2026-27 financial results
- Financial resultsBajaj Healthcare Ltd announces unaudited Q2 & H1 FY27 financial results and key updates
- Acquisition / mergerBajaj Healthcare Limited received NCLT approval for acquisition of Genrx Pharmaceuticals
Other acquisition / merger filings this fortnight
- Acquisition / mergerZen TechnologiesZen Technologies to acquire 51.98% stake in Cogknit Semantics for ₹135.15 crore
- Acquisition / mergerAmber Enterp.Amber Enterprises' subsidiary IL JIN acquires remaining 40% stake in Power-One
- Acquisition / mergerAmber Enterp.Amber Enterprises subsidiary IL JIN acquires 40% stake in Power-One via share swap
- Acquisition / mergerKPI Green EnergyKPI Green Energy’s subsidiary Sun Drops Energia acquires 88.37% stake in DMGEL
- Acquisition / mergerZen TechnologiesZen Technologies to acquire 51.98% stake in Cogknit Semantics for ₹135.15 crore
- Acquisition / mergerJSW SteelJSW Steel Limited announces NCLT sanction of Scheme of Amalgamation with Piombino Steel Limited
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.